Myeloproliferative Disorders
Biology and Management
1st Edition
Published on 26. November 2019
Book
Paperback/Softback
238 pages
978-0-367-45291-9 (ISBN)
Description
With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeutics. Written in an easy-to-follow text myeloproliferative disorders gives the practicing clinician a single source answer to classification, diagnosis, management, and recent advances in this disorder.
More details
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
Professional and scholarly
Professional Reference
Dimensions
Height: 229 mm
Width: 152 mm
Thickness: 13 mm
Weight
351 gr
ISBN-13
978-0-367-45291-9 (9780367452919)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Book
10/2007
1st Edition
CRC Press
€260.41
Article not available at the moment
E-Book
10/2007
CRC Press
€65.99
Available for download
E-Book
10/2007
1st Edition
CRC Press
€65.99
Available for download
Persons
Richard T. Silver Ayalew Tefferi
Content
Preface. Modern classification and diagnostic algorithms in myeloproliferative disorders. Diagnostic utility of bone marrow pathology in myeloproliferative disorders. Molecular pathogenesis of BCR/ABL-negative myeloproliferative disorders. Cytogenetic studies in myeloproliferative disorders. Congenital causes of erythrocytosis and thrombocytosis. Management of polycythemia vera. Management of essential thrombocythemia. Management of myelofibrosis with myeloid metaplasia. Contemporary diagnosis and management of systemic mastocytosis. Modern classification and treatment of primary eosinophilic disorders. Overlap MDS/MPD.